Outcomes the greatest benefit

Tramacere I, Del Giovane C, Filippini G. Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.JAMA. 2016 Jan 26;315(4):409-10. doi: 10.1001/jama.2015.18984.

CLINICAL QUESTION: What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?

BOTTOM LINE: Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.


Each treatment has its pros and cons you need to to know as much as possible so that you can make the best choice for yourself.

Labels: